alking is fundamental to preserving health and independence. An individual's usual pace of walking is also recognized as an indicator of health, risk for dependency, and a predictor of long-term survival. A reduction of gait speed by just 0.1 m/sec provides important information about outcomes in older adults that goes beyond chronologic age, sex, comorbidity, and self-reported function combined.
similar to fast walkers. After adjustment, baseline and change in 6MWT remained independently predictive of long-term outcomes, indicating that walking reflects baseline risk as well as resiliency.
Not all baseline slow walkers are alike, so changes in walking performance provide context. Trajectories of gait speed have been described in other populations. A study of 439 older adults found that change in serially assessed gait speed in primary care clinics was predictive of longterm survival. Whereas 70% of a community population transiently or never improved, 30% had sustained improvement over 1 year of follow-up, usually with treatment of chronic conditions such as congestive heart failure, arthritis, and chronic obstructive pulmonary disease. In fact, gait speed improvement was more predictive of long-term outcomes than other performance measures or self-reported health. 4 In populations with TAVR, symptoms assessed by New York Heart Association class and Kansas City Cardiomyopathy Questionnaire consistently improve after TAVR. 5 However, in the Society of Thoracic Surgeons/American College of Cardiology Transcatheter Valve Therapy Registry, only two-thirds of patients had a favorable outcome 1 year after TAVR, defined as alive with a reasonable quality of life (Kansas City Cardiomyopathy Questionnaire overall score ≥60 and no decline in Kansas City Cardiomyopathy Questionnaire ≥10 points). 6 Evidence supports a correlation between symptom improvement and change in 6MWT at 6 months; patients with improved New York Heart Association class (-1.5 class rank) had change in 6MWT from baseline to 6 months (222-299 meters), but 6MWT did not change for those without symptom improvement (169 to 149 meters). 7 In the article by Altisent et al, 3 the group of slow walkers without improvement had more chronic obstructive pulmonary disease, peripheral vascular disease, and anemia-all known predictors of performance limitation and poor outcomes. Yet patients with chronic lung disease often improve with TAVR according to a subgroup analysis of the PARTNER trial (Placement of Aortic Transcatheter Valves), with those unlikely to improve having the slowest baseline 6MWT (<50 meters) or oxygen dependency. 8 Not all patients with chronic obstructive pulmonary disease or any other high-risk comorbidity are alike, and walking assessments help to further stratify.
Although most improve with TAVR, ways to identify those patients who will not are still needed. The recovery of walking performance introduces a way to assess patients before and after TAVR. Rehabilitation and exercise interventions reduce prevalent frailty in communitydwelling older populations 9 and also improve 6MWT after TAVR. 10 Therefore, baseline slow walkers might undergo prehabilitation to improve strength or mobility to clarify the contribution of frailty to walking performance. Those individuals with comorbid conditions associated with slow gait and lack of TAVR benefit might undergo balloon aortic valvuloplasty to clarify the role of aortic stenosis. In these examples, the trajectory of walking performance can provide a window into risk and resiliency to better identify patients likely to improve with TAVR.
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